Loading...
•
Mar 31
scPharmaceuticals Q1 2025 Earnings Report
scPharmaceuticals posted strong FUROSCIX revenue growth in Q1 2025, driven by increased demand and product expansion into chronic kidney disease.
Key Takeaways
In Q1 2025, scPharmaceuticals achieved $11.8 million in FUROSCIX revenue, a 93% increase from the same period last year. The company filled 13,900 doses and added over 4,200 unique prescribers. While operating expenses grew due to R&D and commercialization, the company maintained a cash balance of $57.5 million.
Generated $11.8 million in FUROSCIX revenue, up 93% YoY.
Filled approximately 13,900 doses in Q1 2025, a 73% increase YoY.
Gross-to-net discount was 23%, up from 19% in Q4 2024.
Reported a net loss of $19.7 million with $57.5 million in cash reserves.
scPharmaceuticals
scPharmaceuticals
scPharmaceuticals Revenue by Segment
Revenue by Segment
FUROSCIX Revenue
CapyFin.com Forward Guidance
scPharmaceuticals expects continued momentum in FUROSCIX growth driven by expanded indication and seasonal patient cost benefits, with additional catalysts like the Autoinjector submission in Q3 2025.
Positive Outlook
- Launched FUROSCIX in second indication (CKD) in April 2025
- Autoinjector program (SCP-111) on track for sNDA submission in Q3 2025
- Increased Medicare patient participation expected to boost Q2 demand
- Growing acceptance among nephrologists for new indication
- Strong fill rate and prescription growth entering Q2 2025
Challenges Ahead
- Higher SG&A and R&D costs increasing operating expenses
- Net loss widened to $19.7M from $14.1M YoY
- Cash balance declined from $75.7M to $57.5M QoQ
- Increased gross-to-net discount may pressure margins
- Stockholders’ equity turned negative at end of Q1 2025